TheraRadar
← Back
Data updated: Mar 29, 2026

VIIV HLTHCARE

Infectious DiseaseImmunology
Biotech

VIIV HLTHCARE is a biotechnology company focused on Infectious Disease, Immunology. Key products include TIVICAY.

1987
Since
19
Drugs
-
Trials
26
Approved (2yr)

Key Drugs

TRIUMEQ PD
abacavir sulfate
1 indications · 2022
CABENUVA KIT
cabotegravir
1 indications · 2021
TIVICAY PD
dolutegravir sodium
1 indications · 2020
APRETUDE
cabotegravir
1 indications · 2021
TRIUMEQ
abacavir sulfate
1 indications · 2014

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

CABENUVA KIT 2025-11-26
Labeling
TRIUMEQ PD 2025-10-28
Labeling
TIVICAY PD 2025-10-28
Labeling
TIVICAY 2025-10-28
Labeling
TRIUMEQ 2025-10-28
Labeling
JULUCA 2025-10-28
Labeling
DOVATO 2025-10-28
Labeling
CABENUVA KIT 2025-04-11
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 65%
11 drugs
Immunology 35%
6 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Infectious Disease, Immunology
Merck big-pharma
Infectious Disease, Immunology
AbbVie big-pharma
Immunology, Infectious Disease
Johnson & Johnson big-pharma
Immunology, Infectious Disease
GSK big-pharma
Infectious Disease, Immunology